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Abstract 
Background: Asthma research has focused on postnatal exposures, but there is recent evidence to indicate 
immune responses might be initiated in fetal period. Systemic Inflammatory processes during pregnancy might 
affect fetal lung development that could increase propensity in the child to develop lung diseases. 
Objective: To identify the association of C-reactive protein (CRP) levels in Pregnant (with stress in second 
trimester), newborn blood samples (cord blood) with childhood wheezing. 
Methods: Serum CRP concentrations (Turbidimetric method) were measured in maternal blood on the 13-17 
weeks of gestation in 32 pregnant women and in the newborn  cord blood after delivery. During1 year the 
frequency of wheezing diseases evaluated by the International Study on Asthma and Allergy in Childhood 
(ISAAC). Results: Maternal C-reactive protein was associated with the wheezing and lower respiratory tract 
infections r=.413*; - p=0.019. Compared to children with cord blood C-reactive protein high level had increased 
risks of wheezing, r=572;  p=0.001 
Conclusion: Our results suggest that elevated maternal and Cord blood CRP levels are associated with wheezing 
and lower respiratory tract infections in the first  years and predictive  asthma young in life. 
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1. Introduction  
Asthma research has focused on postnatal exposures, but there is recent evidence to indicate immune responses 
might be initiated in fetal period. Systemic Inflammatory processes during pregnancy might affect fetal lung 
development that could increase propensity in the child to develop lung diseases  
C-reactive protein is an acute phase protein that increases in response to infectious and non-infectious stimuli, and 
is generally used as a marker for systemic inflammation [1]. Studies have shown that elevated C-reactive protein 
levels are associated with a reduced lung function, COPD, and asthma in adults [2-4] and children [5. Elevated 
maternal C-reactive protein levels during pregnancy lead to fetal growth restriction6, and are associated with 
endothelial dysfunction, vascular dysfunction and suboptimal placental development [7-9]. These findings 
suggest that inflammatory processes in the mother during pregnancy lead to fetal developmental adaptations and a 
greater susceptibility of impaired respiratory health in childhood. Elevated levels of maternal C-reactive protein 
probably have an indirect effect on the developing fetus because the protein does not pass the placenta [11]. The 
underlying pathways might include fetal growth restriction and smaller lungs and airways [12-14], a pro-
inflammatory fetal or newborn status leading to cytokine deregulation, or other adaptations of the infant’s 
immune system subsequently influencing the development of asthma [15, 16, 17]. Cord blood C-reactive protein 
levels reflect fetal levels and can have both direct effects, such as a TH2 skewed immune system, and indirect 
effects, as described for maternal C-reactive protein, on the fetus. Therefore, the timing of elevated C-reactive 
protein levels may have different effects on respiratory health of the child [18, 19, 20]. Thus far, the roles of 
maternal and cord blood C-reactive protein levels in the development of childhood asthma remain unclear. 
2. Materials and methods 
We examined in prospective study, among 32 children followed up from early fetal life, the associations between 
maternal and cord blood C-reactive protein levels with wheezing, respiratory tract infections in the first 1.5 years 
of life. 
Maternal venous blood samples were collected in early pregnancy (median gestational age (13.5, 95% range 9.5 
to 17.8 weeks) and fetal umbilical cord blood samples were collected by neonatologists immediately after 
delivery. High-sensitivity C-reactive protein levels were analyzed using an immunoturbidimetric method. 
Statistics 
During assessment of quantitative indicators, we were calculating mean and standard deviation (Std). In case of 
quantitative indicators reliability of differences between groups was determined by using student t criteria, when 
comparing we assessed dispersion equation by Levene’s Test, selection of appropriate t criteria was done after 
obtained results. Mean frequency (%) was calculated for qualitative indicators, Differences between groups was 
assessed by –2 criteria and by F(Fisher’s) precise criteria. Correlations between factors were determined by 
Spearmen’s rank correlation. The difference was thought to be reliable when p<0.05, mathematical provision was 
performed with use of software package SPSS22. 
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Results 
Of the singleton live births (n=32), data on both maternal and cord blood C-reactive protein levels were available. 
wheezing , lower respiratory tract infections.  
Table 1: Maternal Stress and C-reactive protein 
    Stress Light stress Mild Stress Severe Stress 
 CRP r -0.143 0.033 -0.228 -0.163 
 p 0.435 0.860 0.210 0.374 
 
Maternal C-reactive protein levels were not consistently associated with wheezing, lower respiratory tract 
infections in the child at the age of 1,5 y.  
As compared to children from mothers with C-reactive protein levels in the lowest quarter, children from mothers 
in the highest quarter had an increased risk of wheezing until the age of 1.5 years. 
 
 Figure1: Distribution of frequency(%) of newborn characteristics according to sex 
During increased C-reactive protein level healthy term newborn is reliably less, and low birth weight newborn is 
reliably more compared to its gestation or w/o it, diagnosis of a newborn/RDS, weight <2500,  
Frequency of wheezing morbidity according to cord blood C-reactive protein concentration is given in the 
diagram 
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Figure 2: Distribution of frequency (%) of wheezing morbidity according to cord blood C-reactive protein (CRP) 
concentration 
Morbidity with wheezing is reliably high in increased C-reactive protein group 
According to ambulatory admission frequency there was no reliable difference between increased C-reactive 
protein group and normal level group  
It is important to establish a link between newborn characteristics and cord blood C - reactive protein 
concentration, as well as a link between newborn characteristics itself, for diagnostic and prognostic purposes, 
what was done by correlation analysis.  
Reliable positive correlation with C-reactive protein is seen with newborn low weight in comparison with 
gestation or w/o it - r=.572**; - p=0.001; newborn diagnosis/RDS - r=.413*; - p=0.019;; Referral - r=.572**; - 
p=0.001; morbidity with wheezing - r=.572**; - p=0.001; in-patient setting  - r=.556**; - p=0.001; out-patient 
setting - r=.442*; - p=0.011; <2500 - r=.572**; - p=0.001. 
Reliable negative correlation with C-reactive protein is seen with - - one newborn born in in-patient setting - r=-
.425*; - p=0.015; term newborn - r=-.572**; - p=0.001; duration of breastfeeding  - r=-.569**; - p=0.001; 
Due to the concentration of C-Reactive Protein (CRP) in mother’s blood no reliable differences have been 
revealed among wheezing frequent cases p  0,4481 
Maternal C-reactive protein was not associated with the risks of wheezing and lower respiratory tract infections 
3. Conclusion 
Our results suggest that elevated Cord blood CRP levels are associated with wheezing and lower respiratory tract 
infections in the 1.5 years and predictive asthma young in life. 
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4. Discussion 
Our results suggest that elevated maternal C-reactive protein levels in early pregnancy are not associated with risk 
of wheezing in the first 1.5 years  and an overall higher risk of eczema, whereas cord blood C-reactive protein 
levels are associated with a higher overall risk of wheezing and lower respiratory tract infections. Previous studies 
suggested that children have a threefold increased risk of recurrent wheezing and a more than two fold increased 
risk of recurrent lower respiratory tract infections at the age of 14 months among children in the highest tertile 
compared to the lowest tertile of maternal C-reactive protein levels during pregnancy [10]. We observed a lower 
risk of wheezing in the first year for the highest maternal C-reactive protein levels group and no association of 
maternal C-reactive protein levels with lower respiratory tract infections. The C-reactive protein levels between 
the studies were measured during similar weeks of pregnancy and the 25%-75% ranges were comparable (2.0-7.0 
mg/L vs. 2.3-7.7 mg/L for Morales and his colleagues and our study, respectively). Differences in the observed 
effects are unlikely to be the result of different laboratory methods (regular C-reactive protein levels vs. high 
sensitivity C-reactive protein levels) with different detection limits (2.0 mg/L vs. 0.2 mg/L, respectively) because 
both the lowest tertile and quartile reference group that were used included corresponding low C-reactive protein 
levels. A more likely explanation is that we assessed our outcomes annually and in a larger number of subjects, 
and were able to assess the influence of many potential effect modifiers. Pregnancy can be seen as an 
inflammatory stressor and elevated C-reactive protein levels with values of >10 mg/l are within the normal range 
for pregnant women throughout gestation. The highest quarter might have included mothers with an acute 
systemic inflammation and might have affected the strength of the associations. However, a sensitivity analysis 
excluding mothers with C-reactive protein levels >100 mg/L showed similar effect estimates. As we performed 
multiple tests, we cannot exclude that some results might be a chance finding. However, because of the 
correlation in outcomes we did not apply adjustment for multiple testing. The mechanisms explaining the relation 
between maternal C-reactive protein levels and a reduced risk of wheezing in the first year. The different 
direction of effect estimates between maternal and cord blood C-reactive protein levels may suggest that the 
timing of increased C-reactive protein levels is critical for the association with lung and airway development. 
Early adverse exposures might trigger developmental adaptations in the child, as suggested by the developmental 
origins hypothesis. This could lead to an adapted risk of respiratory symptoms. C-reactive protein cannot pass the 
placenta, thus the suggested association of maternal C-reactive protein levels and wheezing is not likely to be 
direct or causal. C-reactive protein is produced in the liver under IL-6 stimulation, and IL-6 may change the 
TH1/TH2 cell balance by inhibiting TH1 differentiation as well as promotion of TH2 differentiation [21]. A late 
exposure will not result in preventive adaptations, but we suggest that exposure to infections in late pregnancy 
makes the child more responsive to infections. The observed association between cord blood C-reactive protein 
and an early preschool wheezing pattern (supporting information) support the observed associations between cord 
blood C-reactive protein and wheezing and lower respiratory tract infections. Thus, increased cord blood C-
reactive protein levels increase the risk of infections in the first four years of life. Also, after additional 
adjustment for lower respiratory tract infections the estimates attenuated into a non-significant effect. This 
suggests that the association between cord blood C-reactive protein and wheezing is, at least partly, explained by 
infectious mechanisms. Elevated C-reactive protein levels are suggested to be partially driven by an increased 
body mass index [22, 23]. Also, they are suggested to be associated with preeclampsia, subsequently leading to 
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increased risk of wheezing via an impaired placental functioning and its adverse effect on lung development [24, 
27, 28]. However, in our study we did not observe these modifying effects. An elevated C-reactive protein level 
in cord blood might be the result of placental problems like inflammatory lesions [25, 26], a pro-inflammatory 
fetal or newborn status leading to cytokine dysregulation, or other adaptations of the infant’s immune system 
subsequently influencing the development of infections and asthma [10]. We observed a modifying effect of 
gestational age at birth. The effect of elevated C-reactive protein levels on wheezing and lower respiratory tract 
infections were stronger in preterm than in term born children. This might be explained by a combined effect of 
an immature lung development. 
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